Drug Discovery Services Market
Market Insights on Drug Discovery Services covering sales outlook, demand forecast & up-to-date key trends
Drug Discovery Services Market Analysis by Process (Target Selection, Target Validation, Hit-to-Lead Identification, Lead Optimization, Candidate Validation), Type (Chemistry Services and Biology Services), Drug Type (Small-molecule Drugs and Biologics Drugs), Therapeutic Area, End User, & Region - Forecast to 2022-2032
Drug Discovery Services Market Outlook
[250 Pages Report] The global drug discovery services market size was valued at US$ 15.5 Bn in 2021 and is projected to reach a valuation of US$ 32 Bn by 2026 with an expected CAGR of 14.5% from 2022 to 2032.
“New revenue sources in the drug discovery services industry are being driven by portfolio diversification through increased R&D spending and rising demand for outsourced analytical testing services.”
Growing pharmaceutical and biopharmaceutical R&D spending, rising demand for outsourced analytical testing services, initiatives for rare disease and orphan drug research are all driving new income streams in the drug discovery services market.
Stringent rules regulating drug research and animal testing, on the other hand, are projected to limit market expansion to some extent. Drug discovery service companies have a problem due to a scarcity of trained employees.
|
Attributes |
Details |
|
Drug Discovery Services Market CAGR (2022 – 2032) |
14.5% |
|
Drug Discovery Services Market (2026) |
US$ 32 Bn |
|
Drug Discovery Services Market Attraction |
Less stringent regulations make Asia Pacific key market |
Let us know your requirement to get
100% FREE customization
How severe is the COVID-19 Impact on Drug Discovery Services Market?
“During COVID-19 pandemic, the need for the development of a drug or vaccine is projected to have a positive impact on the drug discovery services market.”
Drug discovery and development for the treatment of COVID-19 are being performed by screening both novel and existing drugs for their potential to reduce symptoms and stop viral replication.
Future drug discovery technologies such as high throughput, bioinformatics, and medicinal chemistry are being used more frequently in the drug discovery services market for better drug candidate identification.
Emerging technology (computer-aided drug discovery market) has substantially aided drug discovery, making it more sophisticated, accurate, and less time-consuming. In addition, artificial intelligence (AI) systems are increasingly used in drug discovery and development. This global drug discovery services market trend is projected to continue in the coming years.
How are the Dynamics Impacting Growth of the Drug Discovery Services Market?
“Increased R&D efficiency with large investments dedicates a major amount of development to the market.”
The majority of pharmaceutical, biopharmaceutical, and medical device businesses devote significant resources to developing new medications and technologies. The pharmaceutical sector spends a lot of money on research and development. The research and development pharmaceutical industry brings high-quality, innovative goods to market.
The top pharma companies are enhancing their R&D efficiencies through large R&D investments to see long-term benefits. According to the market analysis, R&D spending in drug discovery services market would expand at a CAGR of 4.2 per cent between 2020 and 2026, reaching USD 254.0 billion.
Outsourcing drug discovery services has emerged as a strategic alternative to offset the shortage of in-house resources required for new product development, as pharma businesses face great pressure to reduce fixed costs. As a result, big pharma is migrating to a leaner business model that mainly relies on outsourcing.
For example, most pharmaceutical and bio-pharmaceutical companies outsource their testing operations throughout R & D to boost profitability, satisfy drug development timeframes, and save money. Most pharmaceutical and bio-pharmaceutical companies outsource their testing operations throughout R&D.
This is evidenced by recent collaborations between large pharmaceutical corporations and contract research organizations (CROs) that provide drug discovery and development services. As a result, rising pharmaceutical R&D spending boosts the market for drug discovery services.
What is the Impact of Regulatory Norms on the Drug Discovery Services Market?
Regulatory agencies place a high priority on ensuring drug safety and efficacy during the approval process. Although these methods ensure the quality of medicines released to the market, they significantly raise the cost of drug development and the final product. This issue can considerably impact a drug's acceptance in price-sensitive emerging markets.
Strict restrictions govern the use of animals in drug development. Mice, rats, fish, amphibians, and reptiles are the most common animals utilized in scientific studies. However, concerns over the ethical use of animals in research have prompted countries to enact animal safety and use legislation, which poses several hurdles to the smooth operation of drug discovery research.
Which Opportunities can the Drug Discovery Services Market Players Cash in On?
Despite the fact that small-molecule pharmaceuticals dominate the global pharmaceutical market, biologics, biosimilars, and large-molecule drugs are gaining market share, primarily due to the introduction of new biologic-based treatments and rising earnings from current biologics. In addition,
Biologics and biosimilars necessitate more specialized testing services than small molecules at each level. Therefore, in the next few years, the growing demand for outsourcing these activities to CROs is likely to fuel the expansion of the drug discovery services market.
What are the Key Drug Discovery Services Market Threats Faced by Players?
“Adoption of new technology and processes on one hand and lack of skilled labours on the other cause imbalance in the adoption of drug discovery services."
Companies must give higher compensations and other incentives to compete effectively; this may impact players' finances and operational outcomes, particularly small-scale analytical testing providers.
In addition, this scarcity of qualified specialists could impede the adoption of new technology and approaches and the market for drug discovery services in the coming years.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystComparative View of Adjacent Drug Discovery Services Market
Drug Discovery Services Market:
|
Attributes |
Drug Discovery Services Market |
|
CAGR (2022 - 2032) |
14.5% |
|
Market Value (2026) |
US$ 32 Bn |
|
Growth Factor |
Readiness to outsource drug discovery services to support market growth. |
|
Opportunity |
Emerging Asia Pacific market hold high attraction quotient. |
|
Key Trends |
Cross-industry collaboration to improve drug efficiency and boost adoption. |
Computer-aided Drug Discovery Market:
|
Attributes |
Computer-aided Drug Discovery Market |
|
CAGR (2022 - 2032) |
15% |
|
Market Value (2026) |
US$ 7.9 Bn |
|
Growth Factor |
Cost-efficiency of drug development process to underpin adoption. |
|
Opportunity |
Availability of high-end software and progressive improvement in their efficiency. |
|
Key Trends |
Strategic tie-ups for product innovation is a go-to market move. |
Artificial Intelligence in Drug Discovery Market:
|
Attributes |
Artificial Intelligence in Drug Discovery Market |
|
CAGR (2022 - 2032) |
40% |
|
Market Value (2026) |
US$ 5 Bn |
|
Growth Factor |
Growing adoption of innovative drug development processes to reduce market times. |
|
Opportunity |
Increased demand for drugs to curb the COVID-19 pandemic. |
|
Key Trends |
Time is money. Manufacturers resort to rapid drug development. |
The drug Discovery services market share is expanding rapidly, owing to the rising market dynamics for pharmaceuticals. Furthermore, factors like technical developments and an increase in the adoption of novel methodologies for discovery, as well as an increase in demand for generic medications and an increase in the number of patents expiring, all contribute to the rise in drug distribution.
Increased research and development in pharmaceutical industry, the evolution of the health industry, the rise in demand for generic medications, the rise in the geriatric population, and technical developments in drug discovery services are all contributing to the market's growth.
Additionally, the quickly growing pharmaceutical sector and the increase in the number of contract development and manufacturing companies that are promoting drug discovery operations boost sales of drug discovery services.
Other factors that positively influence the drug discovery trends include an increase in awareness about chronic diseases, an increase in patient pool, an increase in unmet medical needs, the regular patent expiration of drugs, an improved regulatory framework for drug discovery, and an increase in funding and reimbursement.
While the factors boosting the demand for drug discovery maintain their hold on the market, there are a few significant restraints that limit its growth as well.
The need for a large capital investment with low profit margins, and a comparatively inadequate healthcare system in middle-income and low-income nations, however, impede the drug discovery and development process.
The drug discovery services sector continues to remain heavily regulated which makes the operations complex and removes the layer of adaptability. The years- to decades-long operation can be complicated in the continuous adoption of drug discovery services, and there is almost always a chance that a medicine will fail to advance to the next stage of research.
The lack of predictive accuracy of current animal studies, high drug development costs, limited knowledge of underlying illness mechanics, patient diversity, a lack of endpoints and biomarkers, a high proportion of failed drug trials, and legislative obstacles are all constraints that this long research pathway encounters.
How is the Drug Discovery Services Market Segmented?
In terms of market share, the Hit-To-Lead identification method is the largest segment, and it is projected to maintain its dominance in the drug discovery services market.
The Lead Optimization segment is expected to see increased demand in the drug discovery services market as technology advances and new state-of-the-art facilities arise.
Which Type of Drug Discovery Service Accounts for Largest Market Share?
The medicinal chemistry services segment had the biggest market share in 2018, and it is predicted to increase at a high-double-digit CAGR throughout the forecast period.
The growing trend of pharmaceutical companies to outsource research and development services, as well as the expanding number of drug discovery and development activities and R&D investment, are driving the medicinal chemistry services market forward.
During the projection period 2022–2032, the biological services segment in drug discovery market is expected to increase at a high CAGR.
Which Drug Type in Drug Discovery Market held the Largest Market Share in 2021?
Small molecules accounted for a large portion in the drug discovery services market in 2021, and biologics is predicted to increase at a high CAGR from 2022 to 2032. The growing use of small molecule medications to treat chronic diseases has resulted in the surge in demand for these drugs.
Which Therapeutic Area Segment Dominated the Global Drug Discovery Market?
Oncology dominated the drug discovery services market in terms of therapeutic areas and is predicted to continue to do so throughout the forecast period. Cancer medicines are in high demand due to an increase in cancer cases around the world, making the segment a prominent shareholder in the next years.
An unified Market Research Subscription Platform, built for today’s disparate research needs.
How is the Regional Growth Outlook for Drug Discovery Services Market?
North America is the global leader in research and development spending in the pharmaceutical industry. The region is also the biggest market for bulk medications and ready-to-use dosage forms. The drug discovery services market in the region works as a free economy, with transparent trading practices and anti-competitive actions restricted.
Since biologics is more expensive, the country (U.S.) has a lot of room for biosimilars. As a result, the U.S. drug discovery services market is expected to become one of the primary competitors for biosimilars by 2020.
Remicade, Enbrel, Rituximab, Adalimumab, Infliximab, Etanercept, Darbepoetin Alpha, and other drugs are among the most popular players in the United States. As a result of the factors mentioned above, the drug discovery services market is expected to grow rapidly over the forecast period.
What is the Contribution of AI in the Regional Market for Drug Discovery Services?
The progressive increase in regional healthcare spending aids new pharmaceutical technology advancements.
For example, Bayer and Exscientia, a company that uses artificial intelligence in drug discovery, signed a collaboration agreement in January 2020 to develop and optimize integrated drug discovery services and lead structures for prospective therapeutic candidates in the treatment of cardiovascular and oncological disorders.
How is the Competition in the Drug Discovery Services Market?
The global drug discovery services market is competitive, with Laboratory Corporation of America Holdings (U.S.), Charles River Laboratories International Inc. (U.S.), WuXi AppTec (China), and Thermo Fisher Scientific Inc. (U.S.) collectively accounting for a large portion of the market.
The U.S. - based company Laboratory Corporation of America Holdings is one of the major players in the global drug discovery services market.
An AI-based drug discovery business collaborated with Diamond Light Source and Scripps Research to identify COVID-19 antiviral treatments on March 31, 2020. Over the forecast period, it is expected to contribute to market growth.
These key players in the global drug discovery market focus on a broad spectrum of clients, technology-enabled solutions, investments in joint ventures & partnerships, and extensive quality systems and processes contribute to the company’s drug discovery services market share.
In addition, these companies use organic and inorganic growth techniques such as acquisitions and expansions to increase their share of the global drug discovery services market.
Key Players
- Laboratory Corporation of America Holdings (US)
- Charles River Laboratories International Inc. (US)
- Genscript Biotech Corporation
- Thermo Fisher Scientific Inc. (US)
- Pharmaron Beijing Co., Ltd.
- Evotec SE
- Eurofins Scientific SE
- Pharmaceutical Product Development, Inc.
- Piramal Enterprises Limited
- Syngene International Limited
Key Segment
By Process:
- Target Selection
- Target Validation
- Hit-to-Lead Identification
- Lead Optimization
- Candidate Validation
By Type:
- Chemistry Services
- Biology Services
By Drug Type:
- Small Molecules Drugs
- Biologics Drugs
By Therapeutic Area:
- Neurology
- Infectious and Immune System Diseases
- Digestive System Diseases
- Oncology
- Other Therapeutic Area
By End User:
- Pharmaceutical & Biotechnology Companies
- Academic Institutes
- Manufacturing
- Other End Users
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East and Africa
Frequently Asked Questions
The global drug discovery services market is expected to register a CAGR of 14.5% from 2022 to 2032.
The size of the drug discovery services market is anticipated to be US$ 50.9 Bn by 2032.
The size of the drug discovery services market was worth US$ 15.5 Bn in 2021.
The global drug discovery services industry is dominated by the North American area, which is benefiting from increased government investment.
R&D spending would expand at a CAGR of 4.2% between 2020 and 2026, reaching US$ 254.0 Bn.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Summary of Statistics
1.3. Key Market Characteristics & Attributes
1.4. Fact.MR Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Risks and Trends Assessment
3.1. Risk Assessment
3.1.1. COVID-19 Crisis and Impact on Demand
3.1.2. COVID-19 Impact Benchmark with Previous Crisis
3.1.3. Impact on Market Value (US$ Mn)
3.1.4. Assessment by Key Countries
3.1.5. Assessment by Key Market Segments
3.1.6. Action Points and Recommendation for Suppliers
3.2. Key Trends Impacting the Market
3.3. Formulation and Product Development Trends
4. Market Background
4.1. Market, by Key Countries
4.2. Market Opportunity Assessment (US$ Mn)
4.2.1. Total Available Market
4.2.2. Serviceable Addressable Market
4.2.3. Serviceable Obtainable Market
4.3. Market Scenario Forecast
4.3.1. Demand in optimistic Scenario
4.3.2. Demand in Likely Scenario
4.3.3. Demand in Conservative Scenario
4.4. Investment Feasibility Analysis
4.4.1. Investment in Established Markets
4.4.1.1. In Short Term
4.4.1.2. In Long Term
4.4.2. Investment in Emerging Markets
4.4.2.1. In Short Term
4.4.2.2. In Long Term
4.5. Forecast Factors - Relevance & Impact
4.5.1. Top Companies Historical Growth
4.5.2. Growth in Automation, By Country
4.5.3. Adoption Rate, By Country
4.6. Market Dynamics
4.6.1. Market Driving Factors and Impact Assessment
4.6.2. Prominent Market Challenges and Impact Assessment
4.6.3. Market Opportunities
4.6.4. Prominent Trends in the Global Market & Their Impact Assessment
5. Key Success Factors
5.1. Manufacturers’ Focus on Low Penetration High Growth Markets
5.2. Banking on with Segments High Incremental Opportunity
5.3. Peer Benchmarking
6. Global Market Demand Analysis 2015-2021 and Forecast, 2022-2032
6.1. Historical Market Analysis, 2015-2021
6.2. Current and Future Market Projections, 2022-2032
6.3. Y-o-Y Growth Trend Analysis
7. Global Market Value Analysis 2015-2021 and Forecast, 2022-2032
7.1. Historical Market Value (US$ Mn) Analysis, 2015-2021
7.2. Current and Future Market Value (US$ Mn) Projections, 2022-2032
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Market Analysis 2015-2021 and Forecast 2022-2032, By Process
8.1. Introduction / Key Findings
8.2. Historical Market Value (US$ Mn) and Analysis By Process, 2015-2021
8.3. Current and Future Market Value (US$ Mn) and Analysis and Forecast By Process, 2022-2032
8.3.1. Target Selection
8.3.2. Target Validation
8.3.3. Hit-to-Lead identification
8.3.4. Lead Optimization
8.3.5. Candidate Validation
8.4. Market Attractiveness Analysis By Process
9. Global Market Analysis 2015-2021 and Forecast 2022-2032, By Type
9.1. Introduction / Key Findings
9.2. Historical Market Value (US$ Mn) and Analysis By Type, 2015-2021
9.3. Current and Future Market Value (US$ Mn) and Analysis and Forecast By Type, 2022-2032
9.3.1. Chemistry Services
9.3.2. Biology Services
9.4. Market Attractiveness Analysis By Type
10. Global Market Analysis 2015-2021 and Forecast 2022-2032,By Drug Type
10.1. Introduction / Key Findings
10.2. Historical Market Value (US$ Mn) and AnalysisBy Drug Type, 2015-2021
10.3. Current and Future Market Value (US$ Mn) and Analysis and ForecastBy Drug Type, 2022-2032
10.3.1. Small-molecule Drugs
10.3.2. Biologics Drugs
10.4. Market Attractiveness AnalysisBy Drug Type
11. Global Market Analysis 2015-2021 and Forecast 2022-2032, By Therapeutic Area
11.1. Introduction / Key Findings
11.2. Historical Market Value (US$ Mn) and Analysis By Therapeutic Area, 2015-2021
11.3. Current and Future Market Value (US$ Mn) and Analysis and Forecast By Therapeutic Area, 2022-2032
11.3.1. Oncology
11.3.2. Infectious and Immune System Diseases
11.3.3. Neurology
11.3.4. Digestive System Diseases
11.3.5. Cardiovascular Diseases
11.3.6. Other Therapeutic Area
11.4. Market Attractiveness Analysis By Therapeutic Area
12. Global Market Analysis 2015-2021 and Forecast 2022-2032, By End User
12.1. Introduction / Key Findings
12.2. Historical Market Value (US$ Mn) and Analysis By End User, 2015-2021
12.3. Current and Future Market Value (US$ Mn) and Analysis and Forecast By End User, 2022-2032
12.3.1. Pharmaceutical & Biotechnology Companies
12.3.2. Academic Institutes
12.3.3. Manufacturing
12.3.4. Other End Users
12.4. Market Attractiveness Analysis By End User
13. Global Market Analysis 2015-2021 and Forecast 2022-2032, By Region
13.1. Introduction
13.2. Historical Market Value (US$ Mn) and Analysis By Region, 2015-2021
13.3. Current Market Size (US$ Mn) & Analysis and Forecast By Region, 2022-2032
13.3.1. North America
13.3.2. Latin America
13.3.3. Europe
13.3.4. Asia Pacific
13.3.5. Middle East and Africa (MEA)
13.4. Market Attractiveness Analysis By Region
14. North America Market Analysis 2015-2021 and Forecast 2022-2032
14.1. Introduction
14.2. Pricing Analysis
14.3. Historical Market Value (US$ Mn) and Trend Analysis By Market Taxonomy, 2015-2021
14.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2022-2032
14.4.1. By Country
14.4.1.1. U.S.
14.4.1.2. Canada
14.4.1.3. Rest of North America
14.4.2. By Drug Type
14.4.3. By Process
14.4.4. By Type
14.4.5. By Therapeutic Area
14.4.6. By End User
14.5. Market Attractiveness Analysis
14.5.1. By Country
14.5.2. By Drug Type
14.5.3. By Process
14.5.4. By Type
14.5.5. By Therapeutic Area
14.5.6. By End User
15. Latin America Market Analysis 2015-2021 and Forecast 2022-2032
15.1. Introduction
15.2. Pricing Analysis
15.3. Historical Market Value (US$ Mn) and Trend Analysis By Market Taxonomy, 2015-2021
15.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2022-2032
15.4.1. By Country
15.4.1.1. Brazil
15.4.1.2. Mexico
15.4.1.3. Rest of Latin America
15.4.2. By Drug Type
15.4.3. By Process
15.4.4. By Type
15.4.5. By Therapeutic Area
15.4.6. By End User
15.5. Market Attractiveness Analysis
15.5.1. By Country
15.5.2. By Drug Type
15.5.3. By Process
15.5.4. By Type
15.5.5. By Therapeutic Area
15.5.6. By End User
16. Europe Market Analysis 2015-2021 and Forecast 2022-2032
16.1. Introduction
16.2. Pricing Analysis
16.3. Historical Market Value (US$ Mn) and Trend Analysis By Market Taxonomy, 2015-2021
16.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2022-2032
16.4.1. By Country
16.4.1.1. Germany
16.4.1.2. France
16.4.1.3. U.K.
16.4.1.4. Italy
16.4.1.5. Russia
16.4.1.6. Rest of Europe
16.4.2. By Drug Type
16.4.3. By Process
16.4.4. By Type
16.4.5. By Therapeutic Area
16.4.6. By End User
16.5. Market Attractiveness Analysis
16.5.1. By Country
16.5.2. By Drug Type
16.5.3. By Process
16.5.4. By Type
16.5.5. By Therapeutic Area
16.5.6. By End User
17. Asia Pacific Market Analysis 2015-2021 and Forecast 2022-2032
17.1. Introduction
17.2. Pricing Analysis
17.3. Historical Market Value (US$ Mn) and Trend Analysis By Market Taxonomy, 2015-2021
17.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2022-2032
17.4.1. By Country
17.4.1.1. China
17.4.1.2. Japan
17.4.1.3. South Korea
17.4.1.4. Rest of Asia Pacific
17.4.2. By Drug Type
17.4.3. By Process
17.4.4. By Type
17.4.5. By Therapeutic Area
17.4.6. By End User
17.5. Market Attractiveness Analysis
17.5.1. By Country
17.5.2. By Drug Type
17.5.3. By Process
17.5.4. By Type
17.5.5. By Therapeutic Area
17.5.6. By End User
18. Middle East and Africa Market Analysis 2015-2021 and Forecast 2022-2032
18.1. Introduction
18.2. Pricing Analysis
18.3. Historical Market Value (US$ Mn) and Trend Analysis By Market Taxonomy, 2015-2021
18.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2022-2032
18.4.1. By Country
18.4.1.1. GCC Countries
18.4.1.2. South Africa
18.4.1.3. Turkey
18.4.1.4. Rest of Middle East and Africa
18.4.2. By Drug Type
18.4.3. By Process
18.4.4. By Type
18.4.5. By Therapeutic Area
18.4.6. By End User
18.5. Market Attractiveness Analysis
18.5.1. By Country
18.5.2. By Drug Type
18.5.3. By Process
18.5.4. By Type
18.5.5. By Therapeutic Area
18.5.6. By End User
19. Key Countries Market Analysis 2015-2021 and Forecast 2022-2032
19.1. Introduction
19.1.1. Market Value Proportion Analysis, By Key Countries
19.1.2. Global Vs. Country Growth Comparison
19.2. US Market Analysis
19.2.1. Value Proportion Analysis by Market Taxonomy
19.2.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032
19.2.2.1. By Drug Type
19.2.2.2. By Process
19.2.2.3. By Type
19.2.2.4. By Therapeutic Area
19.2.2.5. By End User
19.3. Canada Market Analysis
19.3.1. Value Proportion Analysis by Market Taxonomy
19.3.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032
19.3.2.1. By Drug Type
19.3.2.2. By Process
19.3.2.3. By Type
19.3.2.4. By Therapeutic Area
19.3.2.5. By End User
19.4. Mexico Market Analysis
19.4.1. Value Proportion Analysis by Market Taxonomy
19.4.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032
19.4.2.1. By Drug Type
19.4.2.2. By Process
19.4.2.3. By Type
19.4.2.4. By Therapeutic Area
19.4.2.5. By End User
19.5. Brazil Market Analysis
19.5.1. Value Proportion Analysis by Market Taxonomy
19.5.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032
19.5.2.1. By Drug Type
19.5.2.2. By Process
19.5.2.3. By Type
19.5.2.4. By Therapeutic Area
19.5.2.5. By End User
19.6. Germany Market Analysis
19.6.1. Value Proportion Analysis by Market Taxonomy
19.6.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032
19.6.2.1. By Drug Type
19.6.2.2. By Process
19.6.2.3. By Type
19.6.2.4. By Therapeutic Area
19.6.2.5. By End User
19.7. France Market Analysis
19.7.1. Value Proportion Analysis by Market Taxonomy
19.7.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032
19.7.2.1. By Drug Type
19.7.2.2. By Process
19.7.2.3. By Type
19.7.2.4. By Therapeutic Area
19.7.2.5. By End User
19.8. Italy Market Analysis
19.8.1. Value Proportion Analysis by Market Taxonomy
19.8.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032
19.8.2.1. By Drug Type
19.8.2.2. By Process
19.8.2.3. By Type
19.8.2.4. By Therapeutic Area
19.8.2.5. By End User
19.9. Russia Market Analysis
19.9.1. Value Proportion Analysis by Market Taxonomy
19.9.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032
19.9.2.1. By Drug Type
19.9.2.2. By Process
19.9.2.3. By Type
19.9.2.4. By Therapeutic Area
19.9.2.5. By End User
19.10. UK Market Analysis
19.10.1. Value Proportion Analysis by Market Taxonomy
19.10.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032
19.10.2.1. By Drug Type
19.10.2.2. By Process
19.10.2.3. By Type
19.10.2.4. By Therapeutic Area
19.10.2.5. By End User
19.11. China Market Analysis
19.11.1. Value Proportion Analysis by Market Taxonomy
19.11.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032
19.11.2.1. By Drug Type
19.11.2.2. By Process
19.11.2.3. By Type
19.11.2.4. By Therapeutic Area
19.11.2.5. By End User
19.12. Japan Market Analysis
19.12.1. Value Proportion Analysis by Market Taxonomy
19.12.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032
19.12.2.1. By Drug Type
19.12.2.2. By Process
19.12.2.3. By Type
19.12.2.4. By Therapeutic Area
19.12.2.5. By End User
19.13. South Korea Market Analysis
19.13.1. Value Proportion Analysis by Market Taxonomy
19.13.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032
19.13.2.1. By Drug Type
19.13.2.2. By Process
19.13.2.3. By Type
19.13.2.4. By Therapeutic Area
19.13.2.5. By End User
19.14. GCC Countries Market Analysis
19.14.1. Value Proportion Analysis by Market Taxonomy
19.14.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032
19.14.2.1. By Drug Type
19.14.2.2. By Process
19.14.2.3. By Type
19.14.2.4. By Therapeutic Area
19.14.2.5. By End User
19.15. South Africa Market Analysis
19.15.1. Value Proportion Analysis by Market Taxonomy
19.15.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032
19.15.2.1. By Drug Type
19.15.2.2. By Process
19.15.2.3. By Type
19.15.2.4. By Therapeutic Area
19.15.2.5. By End User
19.16. Turkey Market Analysis
19.16.1. Value Proportion Analysis by Market Taxonomy
19.16.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032
19.16.2.1. By Drug Type
19.16.2.2. By Process
19.16.2.3. By Type
19.16.2.4. By Therapeutic Area
19.16.2.5. By End User
19.16.3. Competition Landscape and Player Concentration in the Country
20. Market Structure Analysis
20.1. Market Analysis by Tier of Companies
20.2. Market Concentration
20.3. Market Share Analysis of Top Players
20.4. Market Presence Analysis
20.4.1. By Regional footprint of Players
20.4.2. Product footprint by Players
21. Competition Analysis
21.1. Competition Dashboard
21.2. Competition Benchmarking
21.3. Competition Deep Dive
21.3.1. LABORATORY CORPORATION OF AMERICA HOLDINGS
21.3.1.1. Overview
21.3.1.2. Product Portfolio
21.3.1.3. Sales Footprint
21.3.1.4. Strategy Overview
21.3.2. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
21.3.2.1. Overview
21.3.2.2. Product Portfolio
21.3.2.3. Sales Footprint
21.3.2.4. Strategy Overview
21.3.3. GENSCRIPT BIOTECH CORPORATION
21.3.3.1. Overview
21.3.3.2. Product Portfolio
21.3.3.3. Sales Footprint
21.3.3.4. Strategy Overview
21.3.4. THERMO FISHER SCIENTIFIC
21.3.4.1. Overview
21.3.4.2. Product Portfolio
21.3.4.3. Sales Footprint
21.3.4.4. Strategy Overview
21.3.5. PHARMARON BEIJING CO., LTD.
21.3.5.1. Overview
21.3.5.2. Product Portfolio
21.3.5.3. Sales Footprint
21.3.5.4. Strategy Overview
21.3.6. EVOTEC SE
21.3.6.1. Overview
21.3.6.2. Product Portfolio
21.3.6.3. Sales Footprint
21.3.6.4. Strategy Overview
21.3.7. EUROFINS SCIENTIFIC SE
21.3.7.1. Overview
21.3.7.2. Product Portfolio
21.3.7.3. Sales Footprint
21.3.7.4. Strategy Overview
21.3.8. PHARMACEUTICAL PRODUCT DEVELOPMENT, INC.
21.3.8.1. Overview
21.3.8.2. Product Portfolio
21.3.8.3. Sales Footprint
21.3.8.4. Strategy Overview
21.3.9. PIRAMAL ENTERPRISES LIMITED
21.3.9.1. Overview
21.3.9.2. Product Portfolio
21.3.9.3. Sales Footprint
21.3.9.4. Strategy Overview
21.3.10. SYNGENE INTERNATIONAL LIMITED
21.3.10.1. Overview
21.3.10.2. Product Portfolio
21.3.10.3. Sales Footprint
21.3.10.4. Strategy Overview
22. Assumptions and Acronyms Used
23. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 1: Global Value (US$ Mn),By Drug Type, 2015 – 2021
Table 2: Global Value (US$ Mn),By Drug Type, 2022 – 2032
Table 3: Global Value (US$ Mn), By Process, 2015 – 2021
Table 4: Global Value (US$ Mn), By Process, 2022 – 2032
Table 5: Global Value (US$ Mn), By Type, 2015 – 2021
Table 6: Global Value (US$ Mn), By Type, 2022 – 2032
Table 7: Global Value (US$ Mn), By End User, 2015 – 2021
Table 8: Global Value (US$ Mn), By End User, 2022 – 2032
Table 9: Global Value (US$ Mn), By Therapeutic Area, 2015 – 2021
Table 10: Global Value (US$ Mn), By Therapeutic Area, 2022 – 2032
Table 11: Global Drug Discovery Services Market, By Region, 2015 – 2021
Table 12: Global Drug Discovery Services Market, By Region, 2022 – 2032
Table 13: North America Value (US$ Mn),By Drug Type, 2015 – 2021
Table 14: North America Value (US$ Mn),By Drug Type, 2022 – 2032
Table 15: North America Value (US$ Mn), By Process, 2015 – 2021
Table 16: North America Value (US$ Mn), By Process, 2022 – 2032
Table 17: North America Value (US$ Mn), By Type, 2015 – 2021
Table 18: North America Value (US$ Mn), By Type, 2022 – 2032
Table 19: North America Value (US$ Mn), By End User, 2015 – 2021
Table 20: North America Value (US$ Mn), By End User, 2022 – 2032
Table 21: North America Value (US$ Mn), By Therapeutic Area, 2015 – 2021
Table 22: North America Value (US$ Mn), By Therapeutic Area, 2022 – 2032
Table 23: North America Drug Discovery Services Market, By Country, 2015 – 2021
Table 24: North America Drug Discovery Services Market, By Country, 2022 – 2032
Table 25: Latin America Value (US$ Mn),By Drug Type, 2015 – 2021
Table 26: Latin America Value (US$ Mn),By Drug Type, 2022 – 2032
Table 27: Latin America Value (US$ Mn), By Process, 2015 – 2021
Table 28: Latin America Value (US$ Mn), By Process, 2022 – 2032
Table 29: Latin America Value (US$ Mn), By Type, 2015 – 2021
Table 30: Latin America Value (US$ Mn), By Type, 2022 – 2032
Table 31: Latin America Value (US$ Mn), By End User, 2015 – 2021
Table 32: Latin America Value (US$ Mn), By End User, 2022 – 2032
Table 33: Latin America Value (US$ Mn), By Therapeutic Area, 2015 – 2021
Table 34: Latin America Value (US$ Mn), By Therapeutic Area, 2022 – 2032
Table 35: Latin America Drug Discovery Services Market, By Country, 2015 – 2021
Table 36: Latin America Drug Discovery Services Market, By Country, 2022 – 2032
Table 37: Europe Value (US$ Mn),By Drug Type, 2015 – 2021
Table 38: Europe Value (US$ Mn),By Drug Type, 2022 – 2032
Table 39: Europe Value (US$ Mn), By Process, 2015 – 2021
Table 40: Europe Value (US$ Mn), By Process, 2022 – 2032
Table 41: Europe Value (US$ Mn), By Type, 2015 – 2021
Table 42: Europe Value (US$ Mn), By Type, 2022 – 2032
Table 43: Europe Value (US$ Mn), By End User, 2015 – 2021
Table 44: Europe Value (US$ Mn), By End User, 2022 – 2032
Table 45: Europe Value (US$ Mn), By Therapeutic Area, 2015 – 2021
Table 46: Europe Value (US$ Mn), By Therapeutic Area, 2022 – 2032
Table 47: Europe Drug Discovery Services Market, By Country, 2015 – 2021
Table 48: Europe Drug Discovery Services Market, By Country, 2022 – 2032
Table 49: Asia Pacific Value (US$ Mn),By Drug Type, 2015 – 2021
Table 50: Asia Pacific Value (US$ Mn),By Drug Type, 2022 – 2032
Table 51: Asia Pacific Value (US$ Mn), By Process, 2015 – 2021
Table 52: Asia Pacific Value (US$ Mn), By Process, 2022 – 2032
Table 53: Asia Pacific Value (US$ Mn), By Type, 2015 – 2021
Table 54: Asia Pacific Value (US$ Mn), By Type, 2022 – 2032
Table 55: Asia Pacific Value (US$ Mn), By End User, 2015 – 2021
Table 56: Asia Pacific Value (US$ Mn), By End User, 2022 – 2032
Table 57: Asia Pacific Value (US$ Mn), By Therapeutic Area, 2015 – 2021
Table 58: Asia Pacific Value (US$ Mn), By Therapeutic Area, 2022 – 2032
Table 59: Asia Pacific Drug Discovery Services Market, By Country, 2015 – 2021
Table 60: Asia Pacific Drug Discovery Services Market, By Country, 2022 – 2032
Table 61: MEA Value (US$ Mn),By Drug Type, 2015 – 2021
Table 62: MEA Value (US$ Mn),By Drug Type, 2022 – 2032
Table 63: MEA Value (US$ Mn), By Process, 2015 – 2021
Table 64: MEA Value (US$ Mn), By Process, 2022 – 2032
Table 65: MEA Value (US$ Mn), By Type, 2015 – 2021
Table 66: MEA Value (US$ Mn), By Type, 2022 – 2032
Table 67: MEA Value (US$ Mn), By End User, 2015 – 2021
Table 68: MEA Value (US$ Mn), By End User, 2022 – 2032
Table 69: MEA Value (US$ Mn), By Therapeutic Area, 2015 – 2021
Table 70: MEA Value (US$ Mn), By Therapeutic Area, 2022 – 2032
Table 71: MEA Drug Discovery Services Market, By Country, 2015 – 2021
Table 72: MEA Drug Discovery Services Market, By Country, 2022 – 2032
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Market Value (US$ Mn) and Year-on-Year Growth, 2015-2032
Figure 2: Global Market Absolute $ Historical Gain (2015 - 2021) and Opportunity (2022 – 2032), US$ Mn
Figure 3: Global Market Share,By Drug Type, 2022 & 2032
Figure 4: Global Market Y-o-Y Growth Projections,By Drug Type – 2022-2032
Figure 5: Global Market Attractiveness Index,By Drug Type – 2022-2032
Figure 6: Global Market Share, By Process, 2022 & 2032
Figure 7: Global Market Y-o-Y Growth Projections, By Process – 2022-2032
Figure 8: Global Market Attractiveness Index, By Process – 2022-2032
Figure 9: Global Market Share, By End User, 2022 & 2032
Figure 10: Global Market Y-o-Y Growth Projections, By End User – 2022-2032
Figure 11: Global Market Attractiveness Index, By End User – 2022-2032
Figure 12: Global Market Share, By Type, 2022 & 2032
Figure 13: Global Market Y-o-Y Growth Projections, By Type – 2022-2032
Figure 14: Global Market Attractiveness Index, By Type – 2022-2032
Figure 15: Global Market Share, By Therapeutic Area, 2022 & 2032
Figure 16: Global Market Y-o-Y Growth Projections, By Therapeutic Area – 2022-2032
Figure 17: Global Market Attractiveness Index, By Therapeutic Area – 2022-2032
Figure 18: Global Market Share, By Region, 2022 & 2032
Figure 19: Global Market Y-o-Y Growth Projections, By Region – 2022-2032
Figure 20: Global Market Attractiveness Index, By Region – 2022-2032
Figure 21: North America Market Value (US$ Mn) and Year-on-Year Growth, 2015-2032
Figure 22: North America Market Absolute $ Historical Gain (2015 - 2021) and Opportunity (2022 – 2032), US$ Mn
Figure 23: North America Market Share,By Drug Type, 2022 & 2032
Figure 24: North America Market Y-o-Y Growth Projections,By Drug Type – 2022-2032
Figure 25: North America Market Attractiveness Index,By Drug Type – 2022-2032
Figure 26: North America Market Share, By Process, 2022 & 2032
Figure 27: North America Market Y-o-Y Growth Projections, By Process – 2022-2032
Figure 28: North America Market Attractiveness Index, By Process – 2022-2032
Figure 29: North America Market Share, By End User, 2022 & 2032
Figure 30: North America Market Y-o-Y Growth Projections, By End User – 2022-2032
Figure 31: North America Market Attractiveness Index, By End User – 2022-2032
Figure 32: North America Market Share, By Type, 2022 & 2032
Figure 33: North America Market Y-o-Y Growth Projections, By Type – 2022-2032
Figure 34: North America Market Attractiveness Index, By Type – 2022-2032
Figure 35: North America Market Share, By Therapeutic Area, 2022 & 2032
Figure 36: North America Market Y-o-Y Growth Projections, By Therapeutic Area – 2022-2032
Figure 37: North America Market Attractiveness Index, By Therapeutic Area – 2022-2032
Figure 38: North America Market Share, By Country, 2022 & 2032
Figure 39: North America Market Y-o-Y Growth Projections, By Country – 2022-2032
Figure 40: North America Market Attractiveness Index, By Country – 2022-2032
Figure 41: Latin America Market Value (US$ Mn) and Year-on-Year Growth, 2015-2032
Figure 42: Latin America Market Absolute $ Historical Gain (2015 - 2021) and Opportunity (2022 – 2032), US$ Mn
Figure 43: Latin America Market Share,By Drug Type, 2022 & 2032
Figure 44: Latin America Market Y-o-Y Growth Projections,By Drug Type – 2022-2032
Figure 45: Latin America Market Attractiveness Index,By Drug Type – 2022-2032
Figure 46: Latin America Market Share, By Process, 2022 & 2032
Figure 47: Latin America Market Y-o-Y Growth Projections, By Process – 2022-2032
Figure 48: Latin America Market Attractiveness Index, By Process – 2022-2032
Figure 49: Latin America Market Share, By End User, 2022 & 2032
Figure 50: Latin America Market Y-o-Y Growth Projections, By End User – 2022-2032
Figure 51: Latin America Market Attractiveness Index, By End User – 2022-2032
Figure 52: Latin America Market Share, By Type, 2022 & 2032
Figure 53: Latin America Market Y-o-Y Growth Projections, By Type – 2022-2032
Figure 54: Latin America Market Attractiveness Index, By Type – 2022-2032
Figure 55: Latin America Market Share, By Therapeutic Area, 2022 & 2032
Figure 56: Latin America Market Y-o-Y Growth Projections, By Therapeutic Area – 2022-2032
Figure 57: Latin America Market Attractiveness Index, By Therapeutic Area – 2022-2032
Figure 58: Latin America Market Share, By Country, 2022 & 2032
Figure 59: Latin America Market Y-o-Y Growth Projections, By Country – 2022-2032
Figure 60: Latin America Market Attractiveness Index, By Country – 2022-2032
Figure 61: Europe Market Value (US$ Mn) and Year-on-Year Growth, 2015-2032
Figure 62: Europe Market Absolute $ Historical Gain (2015 - 2021) and Opportunity (2022 – 2032), US$ Mn
Figure 63: Europe Market Share,By Drug Type, 2022 & 2032
Figure 64: Europe Market Y-o-Y Growth Projections,By Drug Type – 2022-2032
Figure 65: Europe Market Attractiveness Index,By Drug Type – 2022-2032
Figure 66: Europe Market Share, By Process, 2022 & 2032
Figure 67: Europe Market Y-o-Y Growth Projections, By Process – 2022-2032
Figure 68: Europe Market Attractiveness Index, By Process – 2022-2032
Figure 69: Europe Market Share, By End User, 2022 & 2032
Figure 70: Europe Market Y-o-Y Growth Projections, By End User – 2022-2032
Figure 71: Europe Market Attractiveness Index, By End User – 2022-2032
Figure 72: Europe Market Share, By Type, 2022 & 2032
Figure 73: Europe Market Y-o-Y Growth Projections, By Type – 2022-2032
Figure 74: Europe Market Attractiveness Index, By Type – 2022-2032
Figure 75: Europe Market Share, By Therapeutic Area, 2022 & 2032
Figure 76: Europe Market Y-o-Y Growth Projections, By Therapeutic Area – 2022-2032
Figure 77: Europe Market Attractiveness Index, By Therapeutic Area – 2022-2032
Figure 78: Europe Market Share, By Country, 2022 & 2032
Figure 79: Europe Market Y-o-Y Growth Projections, By Country – 2022-2032
Figure 80: Europe Market Attractiveness Index, By Country – 2022-2032
Figure 81: Asia Pacific Market Value (US$ Mn) and Year-on-Year Growth, 2015-2032
Figure 82: Asia Pacific Market Absolute $ Historical Gain (2015 - 2021) and Opportunity (2022 – 2032), US$ Mn
Figure 83: Asia Pacific Market Share,By Drug Type, 2022 & 2032
Figure 84: Asia Pacific Market Y-o-Y Growth Projections,By Drug Type – 2022-2032
Figure 85: Asia Pacific Market Attractiveness Index,By Drug Type – 2022-2032
Figure 86: Asia Pacific Market Share, By Process, 2022 & 2032
Figure 87: Asia Pacific Market Y-o-Y Growth Projections, By Process – 2022-2032
Figure 88: Asia Pacific Market Attractiveness Index, By Process – 2022-2032
Figure 89: Asia Pacific Market Share, By End User, 2022 & 2032
Figure 90: Asia Pacific Market Y-o-Y Growth Projections, By End User – 2022-2032
Figure 91: Asia Pacific Market Attractiveness Index, By End User – 2022-2032
Figure 92: Asia Pacific Market Share, By Type, 2022 & 2032
Figure 93: Asia Pacific Market Y-o-Y Growth Projections, By Type – 2022-2032
Figure 94: Asia Pacific Market Attractiveness Index, By Type – 2022-2032
Figure 95: Asia Pacific Market Share, By Therapeutic Area, 2022 & 2032
Figure 96: Asia Pacific Market Y-o-Y Growth Projections, By Therapeutic Area – 2022-2032
Figure 97: Asia Pacific Market Attractiveness Index, By Therapeutic Area – 2022-2032
Figure 98: Asia Pacific Market Share, By Country, 2022 & 2032
Figure 99: Asia Pacific Market Y-o-Y Growth Projections, By Country – 2022-2032
Figure 100: Asia Pacific Market Attractiveness Index, By Country – 2022-2032
Figure 101: MEA Market Value (US$ Mn) and Year-on-Year Growth, 2015-2032
Figure 102: MEA Market Absolute $ Historical Gain (2015 - 2021) and Opportunity (2022 – 2032), US$ Mn
Figure 103: MEA Market Share,By Drug Type, 2022 & 2032
Figure 104: MEA Market Y-o-Y Growth Projections,By Drug Type – 2022-2032
Figure 105: MEA Market Attractiveness Index,By Drug Type – 2022-2032
Figure 106: MEA Market Share, By Process, 2022 & 2032
Figure 107: MEA Market Y-o-Y Growth Projections, By Process – 2022-2032
Figure 108: MEA Market Attractiveness Index, By Process – 2022-2032
Figure 109: MEA Market Share, By End User, 2022 & 2032
Figure 110: MEA Market Y-o-Y Growth Projections, By End User – 2022-2032
Figure 111: MEA Market Attractiveness Index, By End User – 2022-2032
Figure 112: MEA Market Share, By Type, 2022 & 2032
Figure 113: MEA Market Y-o-Y Growth Projections, By Type – 2022-2032
Figure 114: MEA Market Attractiveness Index, By Type – 2022-2032
Figure 115: MEA Market Share, By Therapeutic Area, 2022 & 2032
Figure 116: MEA Market Y-o-Y Growth Projections, By Therapeutic Area – 2022-2032
Figure 117: MEA Market Attractiveness Index, By Therapeutic Area – 2022-2032
Figure 118: MEA Market Share, By Country, 2022 & 2032
Figure 119: MEA Market Y-o-Y Growth Projections, By Country – 2022-2032
Figure 120: MEA Market Attractiveness Index, By Country – 2022-2032
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
